Please Wait.....
Report
North America Lymphedema Treatment Market
Market Report I 2025-07-01 I 350 Pages I Data Bridge Market Research
The North America Lymphedema treatment is expected to reach USD 1,268,050.83 thousand by 2032 from USD 560,245.37 thousand in 2024, growing at a CAGR of 11.0% in the forecast period of 2025 to 2032.
Market Segmentation:
North America Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy and Others), Type (Secondary Lymphedema and Primary Lymphedema), Affected Area (Lower Extremity, Upper Extremity and Genitalia), Age Group (Adult, Geriatric and Pediatric), Route of Administration (Oral, Injectable and Topical), End User (Hospital, Speciality Clinics, Ambulatory Surgical Centers and Others) Distribution Channel (Pharmacy, Stores, Direct Tender and Others), Country (U.S., Canada and Mexico) -Industry Trends & Forecast To 2032
Overview of the North America Lymphedema treatment are:
Driver
- Rise in the number of lymphedema cases globally
Restrain
- Significant cost burden associated with lymphedema management
Opportunity
- Expanding opportunities for drug development and regulatory approvals
Market Players:
The key market players for North America Lymphedema treatment are listed below:
- Tactile Medical (U.S.)
- Essity Aktiebolag (publ) (Sweden)
- 3M (U.S.)
- Cardinal Health (U.S.)
- Lohmann & Rauscher GmbH & Co. KG (Germany)
- PAUL HARTMANN AG (Germany)
- medi GmbH & Co. KG (Germany)
- ConvaTec Inc. (U.K.)
- Juzo (Germany)
- Smith + Nephew (U.K.)
- SIGVARIS GROUP (Switzerland)
- Sanyleg Srl (Italy)
- Avet Pharmaceuticals Inc. (U.S.)
- ThermoTek Inc. (U.S.)
- Huntleigh Healthcare Limited (U.K.)
- KOYA MEDICAL (U.S.)
- AIROS Medical, Inc. (U.S.)
- BIOCOMPRESSION SYSTEMS (U.S.)
- Mego Afek ltd. (Israel)
- Thusane (France)
TABLE OF CONTENTS
1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 48
1.4 LIMITATIONS 50
1.5 MARKETS COVERED 50
2 MARKET SEGMENTATION 53
2.1 MARKETS COVERED 53
2.2 GEOGRAPHICAL SCOPE 54
2.3 YEARS CONSIDERED FOR THE STUDY 55
2.4 CURRENCY AND PRICING 55
2.5 DBMR TRIPOD DATA VALIDATION MODEL 56
2.6 MULTIVARIATE MODELLING 59
2.7 PRODUCT TYPE LIFELINE CURVE 59
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.9 DBMR MARKET POSITION GRID 61
2.10 MARKET END USER COVERAGE GRID 62
2.11 VENDOR SHARE ANALYSIS 63
2.12 SECONDARY SOURCES 64
2.13 ASSUMPTIONS 64
3 EXECUTIVE SUMMARY 65
4 PREMIUM INSIGHTS 72
4.1 PORTER'S FIVE FORCES 73
4.2 PESTEL ANALYSIS 74
4.3 INDUSTRY INSIGHTS - 75
4.3.1 MICRO AND MACROECONOMIC FACTORS 75
4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING 75
4.3.3 KEY PRICING STRATEGIES 75
4.3.4 ANALYSIS AND RECOMMENDATION 75
4.4 INNOVATION TRACKER & STRATEGIC ANALYSIS 77
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS 77
4.4.1.1 MERGERS & ACQUISITIONS 77
4.4.1.2 TECHNOLOGY COLLABORATIONS 77
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT 77
4.4.3 STAGE OF DEVELOPMENT 78
4.4.4 TIMELINES & MILESTONES 78
4.4.5 INNOVATION STRATEGIES & METHODOLOGIES 78
4.4.6 RISK ASSESSMENT & MITIGATION 79
4.4.7 FUTURE OUTLOOK 79
4.5 PIPELINE ANALYSIS - NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 81
4.5.1 CLINICAL TRIALS AND PHASE ANALYSIS 81
4.5.2 DRUG THERAPY PIPELINE 81
4.5.3 PHASE III CANDIDATES 82
4.5.4 PHASE II CANDIDATES 82
4.5.5 PHASE I CANDIDATES 82
4.5.6 OTHERS (PRE-CLINICAL AND RESEARCH) 83
4.5.7 CONCLUSION 83
4.6 EPIDEMIOLOGY- 84
4.6.1 INCIDENCE OF LYMPHEDEMA (NORTH AMERICA & BY GENDER) 84
4.6.2 INCIDENCE OF LYMPHEDEMA BY GENDER 84
4.6.3 TREATMENT RATE 84
4.6.4 MORTALITY RATE 84
4.6.5 DRUG ADHERENCE AND THERAPY SWITCH MODEL 85
4.6.6 PATIENT TREATMENT SUCCESS RATES 85
4.7 TARIFF 86
4.7.1 OVERVIEW 86
4.7.2 TARIFF STRUCTURES 86
4.7.2.1 North America vs. Regional Tariff Structures 86
4.7.2.2 United States: Medicare/Medicaid Tariff Policies, CMS Pricing Models 86
4.7.2.3 European Union: Cross-border Tariff Regulations and Reimbursement Policies 87
4.7.2.4 Asia-Pacific: Government-imposed Tariffs on Imported Medical Products 87
4.7.2.5 Emerging Markets: Challenges in Tariff Implementation 87
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 87
4.7.3.1 Import Duties on Prescription Drugs vs. Generics 87
4.7.3.2 Impact on Drug Affordability and Access 87
4.7.3.3 Key Trade Agreements Affecting Pharmaceutical Tariffs 88
4.7.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS 88
4.7.4.1 Cost Burden on Hospitals and Healthcare Facilities 88
4.7.4.2 Effect on Patient Affordability and Insurance Coverage 88
4.7.4.3 Tariffs and Their Role in Medical Tourism 88
4.7.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 88
4.7.5.1 WTO Regulations on Healthcare Tariffs 88
4.7.5.2 Impact of Trade Wars on the Healthcare Supply Chain 88
4.7.5.3 Role of Free Trade Agreements (FTAs) in Reducing Tariffs 88
4.7.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 88
4.7.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 89
5 REGULATORY FRAMEWORK- 90
5.1 NORTH AMERICA 91
5.2 SOUTH AMERICA 92
5.3 EUROPE 93
5.4 ASIA-PACIFIC 94
5.5 MIDDLE EAST & AFRICA 95
6 MARKET OVERVIEW 96
6.1 DRIVERS 98
6.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES GLOBALLY 98
6.1.2 INCREASE IN THE PREVALENCE OF CANCERS 99
6.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 99
6.1.4 AVAILABILITY AND ADVANCEMENT OF MULTIPLE THERAPEUTIC OPTIONS 100
6.2 RESTRAINTS 102
6.2.1 SIGNIFICANT COST BURDEN ASSOCIATED WITH LYMPHEDEMA MANAGEMENT 102
6.2.2 LACK OF AWARENESS ABOUT THE DISEASE 103
6.3 OPPORTUNITIES 104
6.3.1 EXPANDING OPPORTUNITIES FOR DRUG DEVELOPMENT AND REGULATORY APPROVALS 104
6.3.2 STRATEGIC COLLABORATIONS AND ALLIANCES AMONG INDUSTRY STAKEHOLDERS 104
6.4 CHALLENGES 105
6.4.1 ABSENCE OF A DEFINITIVE CURATIVE TREATMENT 105
6.4.2 RESTRICTIVE AND INCONSISTENT REIMBURSEMENT POLICIES 106
7 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 107
7.1 OVERVIEW 108
7.2 COMPRESSION THERAPY 111
7.3 SURGERY 113
7.4 DRUG THERAPY 114
7.5 LASER THERAPY 115
7.6 OTHERS 116
8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE 117
8.1 OVERVIEW 118
8.2 SECONDARY LYMPHEDEMA 121
8.3 PRIMARY LYMPHEDEMA 122
9 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 123
9.1 OVERVIEW 124
9.2 LOWER EXTREMITY 127
9.3 UPPER EXTREMITY 127
9.4 GENITALIA 128
10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 129
10.1 OVERVIEW 130
10.2 ADULT 133
10.3 GERIATRIC 133
10.4 PEDIATRIC 134
11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 135
11.1 OVERVIEW 136
11.2 ORAL 139
11.3 INJECTABLE 139
11.4 TOPICAL 140
12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER 141
12.1 OVERVIEW 142
12.2 HOSPITAL 145
12.3 SPECIALTY CLINICS 145
12.4 AMBULATORY SURGICAL CENTERS 146
12.5 OTHERS 146
13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 147
13.1 OVERVIEW 148
13.2 PHARMACY STORES 151
13.3 DIRECT TENDER 151
13.4 OTHERS 152
14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY REGION 153
14.1 NORTH AMERICA 156
14.1.1 U.S. 162
14.1.2 CANADA 168
14.1.3 MEXICO 173
15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE 178
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 178
16 SWOT ANALYSIS 179
17 COMPANY PROFILE 180
17.1 TACTILE MEDICAL 180
17.1.1 COMPANY SNAPSHOT 180
17.1.2 REVENUE ANALYSIS 180
17.1.3 COMPANY SHARE ANALYSIS 181
17.1.4 PRODUCT PORTFOLIO 181
17.1.5 RECENT DEVELOPMENT 182
17.2 ESSITY AKTIEBOLAG (PUBL) 183
17.2.1 COMPANY SNAPSHOT 183
17.2.2 REVENUE ANALYSIS 183
17.2.3 COMPANY SHARE ANALYSIS 184
17.2.4 PRODUCT PORTFOLIO 184
17.2.5 RECENT DEVELOPMENT 185
17.3 3M 186
17.3.1 COMPANY SNAPSHOT 186
17.3.2 REVENUE ANALYSIS 186
17.3.3 COMPANY SHARE ANALYSIS 187
17.3.4 PRODUCT PORTFOLIO 187
17.3.5 RECENT DEVELOPMENTS 187
17.4 CARDINAL HEALTH 188
17.4.1 COMPANY SNAPSHOT 188
17.4.2 REVENUE ANALYSIS 188
17.4.3 COMPANY SHARE ANALYSIS 189
17.4.4 PRODUCT PORTFOLIO 189
17.4.5 RECENT DEVELOPMENT 190
17.5 LOHMANN & RAUSCHER GMBH & CO. KG 191
17.5.1 COMPANY SNAPSHOT 191
17.5.2 COMPANY SHARE ANALYSIS 191
17.5.3 PRODUCT PORTFOLIO 192
17.5.4 RECENT DEVELOPMENT 193
17.6 AIROS MEDICAL, INC. 194
17.6.1 COMPANY SNAPSHOT 194
17.6.2 PRODUCT PORTFOLIO 194
17.6.3 RECENT DEVELOPMENT 195
17.7 ARJO 196
17.7.1 COMPANY SNAPSHOT 196
17.7.2 REVENUE ANALYSIS 196
17.7.3 PRODUCT PORTFOLIO 197
17.7.4 RECENT DEVELOPMENTS 197
17.8 AVET PHARMACEUTICALS INC. 198
17.8.1 COMPANY SNAPSHOT 198
17.8.2 PRODUCT PORTFOLIO 198
17.8.3 RECENT DEVELOPMENT 198
17.9 BAUERFEIND 199
17.9.1 COMPANY SNAPSHOT 199
17.9.2 PRODUCT PORTFOLIO 199
17.9.3 RECENT DEVELOPMENTS 200
17.10 BIOCOMPRESSION SYSTEMS 201
17.10.1 COMPANY SNAPSHOT 201
17.10.2 PRODUCT PORTFOLIO 201
17.10.3 RECENT DEVELOPMENT 205
17.11 CONVATEC INC. 206
17.11.1 COMPANY SNAPSHOT 206
17.11.2 PRODUCT PORTFOLIO 206
17.11.3 RECENT DEVELOPMENT 207
17.12 ENOVIS CORPORATION 208
17.12.1 COMPANY SNAPSHOT 208
17.12.2 REVENUE ANALYSIS 208
17.12.3 PRODUCT PORTFOLIO 209
17.12.4 RECENT DEVELOPMENTS 209
17.13 HUNTLEIGH HEALTHCARE LIMITED 210
17.13.1 COMPANY SNAPSHOT 210
17.13.2 PRODUCT PORTFOLIO 210
17.13.3 RECENT DEVELOPMENT 211
17.14 IMPEDIMED LIMITED 212
17.14.1 COMPANY SNAPSHOT 212
17.14.2 REVENUE ANALYSIS 212
17.14.3 PRODUCT PORTFOLIO 213
17.14.4 RECENT DEVELOPMENT/NEWS 213
17.15 JODAS EXPOIM PVT. LTD. 214
17.15.1 COMPANY SNAPSHOT 214
17.15.2 PRODUCT PORTFOLIO 214
17.15.3 RECENT DEVELOPMENT 214
17.16 JUZO 215
17.16.1 COMPANY SNAPSHOT 215
17.16.2 PRODUCT PORTFOLIO 215
17.16.3 RECENT DEVELOPMENT 216
17.17 KOYA MEDICAL 217
17.17.1 COMPANY SNAPSHOT 217
17.17.2 PRODUCT PORTFOLIO 217
17.17.3 RECENT DEVELOPMENT 217
17.18 LLC BINNOPHARM GROUP 218
17.18.1 COMPANY SNAPSHOT 218
17.18.2 PRODUCT PORTFOLIO 218
17.18.3 RECENT DEVELOPMENT 218
17.19 MCKESSON MEDICAL-SURGICAL INC. 219
17.19.1 COMPANY SNAPSHOT 219
17.19.2 REVENUE ANALYSIS 220
17.19.3 PRODUCT PORTFOLIO 220
17.19.4 RECENT DEVELOPMENT 221
17.20 MEDI GMBH & CO. KG 222
17.20.1 COMPANY SNAPSHOT 222
17.20.2 PRODUCT PORTFOLIO 222
17.20.3 RECENT DEVELOPMENT 224
17.21 MEDTRONIC 225
17.21.1 COMPANY SNAPSHOT 225
17.21.2 REVENUE ANALYSIS 225
17.21.3 PRODUCT PORTFOLIO 226
17.21.4 RECENT DEVELOPMENTS 227
17.22 MEGO AFEK LTD 228
17.22.1 COMPANY SNAPSHOT 228
17.22.2 PRODUCT PORTFOLIO 228
17.22.3 RECENT DEVELOPMENT 230
17.23 PAUL HARTMANN AG 231
17.23.1 COMPANY SNAPSHOT 231
17.23.2 REVENUE ANALYSIS 231
17.23.3 PRODUCT PORTFOLIO 232
17.23.4 RECENT DEVELOPMENT 232
17.24 PERFORMANCE HEALTH 233
17.24.1 COMPANY SNAPSHOT 233
17.24.2 PRODUCT PORTFOLIO 233
17.24.3 RECENT DEVELOPMENTS 235
17.25 PURETECH HEALTH INC 236
17.25.1 COMPANY SNAPSHOT 236
17.25.2 PIPELINE PORTFOLIO 236
17.25.3 RECENT DEVELOPMENT 237
17.26 SANYLEG SRL A SOCIO UNICO 238
17.26.1 COMPANY SNAPSHOT 238
17.26.2 PRODUCT PORTFOLIO 238
17.26.3 RECENT DEVELOPMENT 239
17.27 SIGVARIS GROUP 240
17.27.1 COMPANY SNAPSHOT 240
17.27.2 PRODUCT PORTFOLIO 240
17.27.3 RECENT DEVELOPMENTS 242
17.28 SMITH+NEPHEW 243
17.28.1 COMPANY SNAPSHOT 243
17.28.2 REVENUE ANALYSIS 243
17.28.3 PRODUCT PORTFOLIO 244
17.28.4 RECENT DEVELOPMENT 244
17.29 THERMOTEK 245
17.29.1 COMPANY SNAPSHOT 245
17.29.2 PRODUCT PORTFOLIO 245
17.29.3 RECENT DEVELOPMENT 245
17.30 THUASNE 246
17.30.1 COMPANY SNAPSHOT 246
17.30.2 PRODUCT PORTFOLIO 246
17.30.3 RECENT DEVELOPMENT 246
17.31 VIATRIS INC. 247
17.31.1 COMPANY SNAPSHOT 247
17.31.2 REVENUE ANALYSIS 247
17.31.3 PRODUCT PORTFOLIO 248
17.31.4 RECENT DEVELOPMENT 248
17.32 WHITE SWAN PHARMACEUTICAL 249
17.32.1 COMPANY SNAPSHOT 249
17.32.2 PRODUCT PORTFOLIO 249
17.32.3 RECENT DEVELOPMENTS 250
18 QUESTIONNAIRE 251
19 RELATED REPORTS 255
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security